About
Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.
Technologies
Google Tag Manager
Ubuntu
WordPress.org
reCAPTCHA
Woo Commerce
Apache
Mobile Friendly
Shutterstock
Keywords
precision diagnostics
strategic partnerships
cost-effective diagnostics
healthcare
d2c
biotechnology
global healthcare solutions
medical research
biomarker validation
non-invasive
patient outcomes
early lung cancer detection
blood plasma testing
research and development in the physical
engineering
and life sciences
clinical validation
diagnostic pathway
proprietary immunoassay
blood test
regulatory approval
ciz1b variant
biomarker detection
high sensitivity detection
b2b
non-invasive blood test
early detection
cancer survival
medical diagnostics
ciz1 protein
Company Information
-
Employees 4
-
Founded 2001
-
Total Funding $440227
Location
London, United Kingdom
